The authors present an updated version of The Cancer-Immunity Cycle 1 , the current intellectual framework for immuno-oncology research and development Article covers the mechanisms by which innate...

IPH5401 dose-escalation study in advanced solid tumors, STELLAR-001, shows manageable safety profile Initiation of two expansion cohorts in non-small cell lung cancer (NSCLC) with secondary resistance...

Innate Pharma SA (the “Company” or “Innate” - Euronext Paris: FR0010331421 – IPH), today announced that AstraZeneca (LSE/STO/NYSE: AZN) will advance monalizumab into a Phase III randomized clinical...

Preliminary results of IPH5401 STELLAR-001, a dose escalation Phase I study in patients with advanced solid tumors 1-year survival data of monalizumab in combination with cetuximab in h ead and neck...

INNATE PHARMA S.A. (Euronext Paris: IPH – ISIN: FR0010331421) (“ Innate ” or the “ Company ”), a French biotechnology company focused on discovering, developing and commercializing first-in-class...

Initiation of multi-cohort IPH4102 Phase II clinical trial (TELLOMAK) Sézary Syndrome cohort designed to be pivotal; preclinical data supports evaluating larger subsets of patients with T-cell...

Data to date demonstrate high activity and favorable safety profile in Sézary syndrome, an aggressive form of cutaneous T-cell lymphoma (CTCL) International IPH4102 TELLOMAK Phase II clinical trial in...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), today announced that it will host a key opinion leader (KOL) call focused on the topic of IPH4102 “TELLOMAK” clinical trial...

Innate Pharma, S.A. (Euronext Paris: IPH) today announced that it plans to conduct a registered public offering of its ordinary shares, in the form of American Depositary Shares (“ADSs”), in the...

Multicohort, multi-center, international Phase II study to evaluate the efficacy and safety of IPH4102 in patients with advanced T-cell lymphoma is ongoing Sézary syndrome cohort of the TELLOMAK study...